Lincoln Pharmaceuticals (NSE:LINCOLN) Cyclically Adjusted PB Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
83 GF Score
Price ₹612.25
GF Value ₹712.46
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lincoln Pharmaceuticals  (NSE:LINCOLN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Lincoln Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 2.09 3.13 2.57 2.29

Lincoln Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.29 0.00 2.29 0.00

NSE:LINCOLN vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


NSE:LINCOLN
83GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lincoln Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lincoln Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lincoln Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Lincoln Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 80.516 105.961 127.169
201612 0.000 105.196 0.000
201703 96.192 105.196 153.033
201706 0.000 107.109 0.000
201709 105.822 109.021 162.446
201712 0.000 109.404 0.000
201803 112.109 109.786 170.898
201806 0.000 111.317 0.000
201809 125.864 115.142 182.942
201812 0.000 115.142 0.000
201903 156.544 118.202 221.644
201906 0.000 120.880 0.000
201909 148.664 123.175 201.989
201912 0.000 126.235 0.000
202003 156.544 124.705 210.086
202006 0.000 127.000 0.000
202009 174.514 130.118 224.459
202012 0.000 130.889 0.000
202103 183.196 131.771 232.671
202106 0.000 134.084 0.000
202109 206.512 135.847 254.413
202112 0.000 138.161 0.000
202203 216.115 138.822 260.538
202206 0.000 142.347 0.000
202209 233.980 144.661 270.690
202212 0.000 145.763 0.000
202303 250.861 146.865 285.865
202306 0.000 150.280 0.000
202309 272.585 151.492 301.132
202312 0.000 152.924 0.000
202403 295.974 153.035 323.675
202406 0.000 155.789 0.000
202409 319.153 157.882 338.307
202412 0.000 158.323 0.000
202503 335.331 157.552 356.201
202506 0.000 159.755 0.000
202509 357.348 162.289 368.508
202512 0.000 163.281 0.000
202603 378.249 164.272 385.352
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹612.25 is trading 14.1% below its estimated GF Value™ of ₹712.46. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹712.46 vs. price of ₹612.25 (14.1% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
83GF Score

Get the complete analysis for NSE:LINCOLN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹612.25
Price
₹712.46
GF Value